Annual report pursuant to Section 13 and 15(d)

Deferred Research And Development Arrangements (Details)

v3.3.1.900
Deferred Research And Development Arrangements (Details) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2003
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Deferred Research and Development Arrangement $ 525,000 $ 600,000    
Rexgene [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development arrangement, one-time fee       $ 1,500,000
Reduction of research and development expenses $ 75,000 75,000 $ 75,000  
Research and development period 20 years      
Deferred Research and Development Arrangement $ 525,000 600,000    
Royalties paid, percentage of net sales 3.00%      
Teva Pharmaceutical Industries, Ltd. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Reduction of research and development expenses   158,630 $ 717,730  
Deferred Research and Development Arrangement   0    
Proceeds remaining   $ 0